Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-cola Euro. Regulatory News (CCEP)

Share Price Information for Coca-cola Euro. (CCEP)

Share Price is delayed by 15 minutes
Get Live Data
7,390.00    5.00 (0.07%)
Bid:
7,395.00
Ask:
7,400.00
Spread: 5.00 (0.068%)
Market Cap: £32.72b
CCEP Live PriceLast checked at - London Stock Exchange

Intraday Coca-cola Euro. Share Chart

Transfer to ESCC Category

15 Nov 2024 08:01

RNS Number : 3355M
Coca-Cola Europacific Partners plc
15 November 2024
 

THIS ANNOUNCEMENT DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE BASIS FOR ANY OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SHARES OR OTHER SECURITIES IN THE COMPANY NOR SHALL IT FORM THE BASIS FOR ANY CONTRACT OR COMMITMENT WHATSOEVER.

15 November 2024

Coca-Cola Europacific Partners plc

 

Transfer to the Equity Shares (Commercial Companies) category

Further to the announcement on 18 October 2024, Coca-Cola Europacific Partners plc ("CCEP" or the "Company") is pleased to announce the approval by the Financial Conduct Authority (the "FCA") of the transfer of the listing category of its ordinary shares from the Equity Shares (Transition) category to the Equity Shares (Commercial Companies) category of the Official List of the FCA (the "Transfer") which became effective at 8:00 a.m. (GMT) today.

Following the transfer and subject to other conditions being met, including a sufficient volume of its trading in the ordinary shares migrating to UK equity trading venues1, the Company should, subject to FTSE approval, be eligible in due course for admission to the FTSE UK Index Series.

The FTSE UK Index Series Guide to Calculation Method for the Median Liquidity Test ("the Liquidity Test") requires that as a pre-requisite to future FTSE indexation eligibility, a minimum of 0.025% of the Company's traded free float to be traded on UK equity trading venues1 against the sterling quote over certain periods. This is calculated on a median monthly basis and is currently equivalent to c.51k (or c. £3.1m) ordinary shares per day. Subject to the outcome of the Liquidity Test being satisfactory, in each month from November 2024 up to and including February 2025, the earliest it could be satisfied is ahead of FTSE Russell's quarterly rebalancing review in March 2025. There can be no certainty that the Liquidity Test will be met.

About CCEP

CCEP is one of the world's leading consumer goods companies. We make, move and sell some of the world's most loved brands - serving nearly 600 million consumers and helping over 4 million customers across 31 countries grow. We combine the strength and scale of a large, multi-national business with an expert, local knowledge of the customers we serve and communities we support.

For more information about CCEP, please visit www.cocacolaep.com & follow CCEP on LinkedIn @CCEP. For a copy of CCEP's latest factsheet: Presentation Title (cocacolaep.com)

 

Enquiries

Corporate broker, joint sponsor and joint financial adviser BNP Paribas: Virginia Khoo virginia.khoo@uk.bnpparibas.com

Corporate broker, joint sponsor and joint financial adviser Deutsche Numis: Lewis Burnett lewis.burnett@dbnumis.com

General Counsel and Company Secretary: Clare Wardle secretariat@ccep.com

Investor Relations: Sarah Willett sarah.willett@ccep.com

Media: ccep@portland-communications.com

 

1 Section 2.1.6 of the FTSE UK Index Series Guide to Calculation Method for the Median Liquidity Test, v2.9 October 2024, lists volumes trading on the following venues which will be aggregated for the purpose of the liquidity test; The London Stock Exchange, CBOE CXE, CBOE BXE and CBOE OTC.

 

Forward-Looking Statements

This announcement contains statements, estimates or projections that constitute "forward-looking statements" concerning the financial condition, performance, strategy and objectives of Coca-Cola Europacific Partners plc and its subsidiaries (together CCEP or the Group). Generally, the words "ambition", "target", "aim", "believe", "expect", "intend", "estimate", "anticipate", "project", "plan", "seek", "may", "could", "would", "should", "might", "will", "forecast", "outlook", "guidance", "possible", "potential", "predict", "objective" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks that could cause actual results to differ materially from CCEP's historical experience and present expectations or projections including that there can be no assurance whether or when our ordinary shares will meet the Liquidity Test or be admitted to FTSE UK Index Series. As a result, undue reliance should not be placed on forward-looking statements, which speak only as of the date on which they are made.

 

Due to these risks, CCEP's actual future financial condition, results of operations, and business activities, including its results, dividend payments, capital and leverage ratios, growth, including growth in revenue, cost of sales per unit case and operating profit, free cash flow, market share, tax rate, efficiency savings, achievement of sustainability goals, including net zero emissions and recycling initiatives, capital expenditures, and ability to remain in compliance with existing and future regulatory compliance, may differ materially from the plans, goals, expectations and guidance set out in forward-looking statements. These risks may also adversely affect CCEP's share price. Additional risks that may impact CCEP's future financial condition and performance are identified in filings with the SEC which are available on the SEC's website at www.sec.gov. CCEP does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required under applicable rules, laws and regulations. Any or all of the forward-looking statements contained in this filing and in any other of CCEP's public statements may prove to be incorrect.

 

End.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUSRWRSUUAAAA
Date   Source Headline
12th Jun 20264:30 pmRNSDirector/PDMR Shareholding
5th Jun 20263:30 pmRNSDirector/PDMR Shareholding
3rd Jun 202612:30 pmRNSDirector/PDMR Shareholding
1st Jun 20261:30 pmRNSTotal Voting Rights
29th May 20261:00 pmRNSResult of AGM
21st May 20263:30 pmRNSDirector/PDMR Shareholding
18th May 202611:00 amRNSLetter to Shareholders
1st May 20264:15 pmRNSDirector/PDMR Shareholding
1st May 20261:30 pmRNSTotal Voting Rights
28th Apr 20267:00 amRNSQ1 Trading Update & Interim Dividend Declaration
27th Apr 20263:00 pmRNSTransactions in Own Shares
22nd Apr 20262:15 pmRNSDirector/PDMR Shareholding
20th Apr 20261:30 pmRNSTransactions in Own Shares
16th Apr 20269:15 amRNSNotice of AGM
15th Apr 202610:30 amRNSDirector/PDMR Shareholding
13th Apr 202612:30 pmRNSTransaction in Own Shares
10th Apr 202611:00 amRNSSID Appointment and Board Committee Changes
7th Apr 20262:00 pmRNSTransaction in Own Shares
1st Apr 20262:30 pmRNSTotal Voting Rights
1st Apr 202611:00 amRNSChange of Company Secretary
30th Mar 20263:30 pmRNSTransactions in Own Shares
27th Mar 20269:00 amRNSDirector/PDMR Shareholding
24th Mar 202612:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20267:00 amRNSTransactions in Own Shares
20th Mar 20264:45 pmRNSDirector/PDMR Shareholding
20th Mar 20267:00 amRNSTransactions in Own Shares
19th Mar 20267:00 amRNSTransactions in Own Shares
18th Mar 20267:00 amRNSTransactions in Own Shares
17th Mar 20267:00 amRNSTransactions in Own Shares
17th Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20265:00 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20267:00 amRNSTransactions in Own Shares
13th Mar 202612:11 pmRNSAnnual Financial Report
13th Mar 202612:11 pmRNSAnnual Financial Report
13th Mar 20267:00 amRNSTransactions in Own Shares
13th Mar 20267:00 amRNSTransactions in Own Shares
12th Mar 20267:00 amRNSTransactions in Own Shares
12th Mar 20267:00 amRNSTransactions in Own Shares
11th Mar 20267:00 amRNSTransactions in Own Shares
10th Mar 20267:00 amRNSTransactions in Own Shares
9th Mar 20267:00 amRNSTransactions in Own Shares
6th Mar 20267:00 amRNSTransactions in Own Shares
5th Mar 20267:00 amRNSTransactions in Own Shares
4th Mar 20264:00 pmRNSDirectorate change
4th Mar 20267:00 amRNSTransactions in Own Shares
3rd Mar 20265:13 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:00 pmRNSHolding(s) in Company
3rd Mar 20267:00 amRNSTransactions in Own Shares
2nd Mar 20261:15 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.